For research use only
| Cat No. | ABC-X0070C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
KIF5B-RET (V738A) BAF3 Cell Line enables investigation of RET-driven oncogenesis and evaluation of drug responses in RET-altered hematologic models.
Human KIF5B_RET (V738A) BAF3 Cell Line is a murine Ba/F3 cell model engineered to express the KIF5B-RET fusion with a V738A mutation. Lentiviral vectors are used for stable integration, and cells are validated by qRT-PCR under passage numbers <P20. Target The KIF5B-RET fusion is an oncogenic driver identified in non-small cell lung cancer (NSCLC), and the V738A mutation further enhances RET kinase activity. The fusion protein promotes persistent MAPK and PI3K/AKT signaling, driving proliferation and survival in tumor cells. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0070C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This overexpression model is optimal for studying RET fusion oncogenicity and drug responses. It supports development of RET inhibitors and evaluation of resistance mutations in RET-driven NSCLC.